Can adding venetoclax let CLL patients pause therapy?
NCT ID NCT06524375
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This phase 2 trial is testing whether adding venetoclax to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) achieve very deep remission. The goal is to see if patients can then safely stop all treatment for a period. The study involves 118 adults who have been on a BTK inhibitor for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Oncology Partners of Maryland, PA
Bethesda, Maryland, 20817-1915, United States
-
Asante Rogue Regional Medical Center
Medford, Oregon, 97504-8332, United States
-
Astera Cancer Care East Brunswick
East Brunswick, New Jersey, 08816-4096, United States
-
Cancer Specialists of North Florida
Jacksonville, Florida, 32256-6932, United States
-
Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center
Boston, Massachusetts, 02215-5418, United States
-
Fort Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana, 46804, United States
-
Highlands Oncology Group
Springdale, Arkansas, 72762, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Mission Blood and Cancer - MercyOne Cancer Center
Des Moines, Iowa, 50314-3030, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130-2042, United States
-
Nebraska Cancer Specialists St Francis - Grand Island
Grand Island, Nebraska, 68803, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Oncology Hematology Care Inc - Cincinnati - USOR
Cincinnati, Ohio, 45236-2725, United States
-
Rocky Mountain Cancer Centers (Aurora) - USOR
Aurora, Colorado, 80012-5405, United States
-
San Juan Oncology Associates, PC
Farmington, New Mexico, 87401, United States
-
Tennessee Oncology - Midtown
Nashville, Tennessee, 37203, United States
-
Tennessee Oncology, PLLC - Chattanooga
Chattanooga, Tennessee, 37404, United States
-
Texas Oncology- Northeast Texas
Tyler, Texas, 75702, United States
-
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, 97401-6043, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (a targeted drug) added to a BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib)
What this could lead to
If successful, this could allow some CLL patients to stop treatment temporarily while keeping the disease under control.
What could go wrong
This is a small, early-phase trial without a comparison group. Adding venetoclax may increase side effects, and not all patients will achieve deep remission.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.